TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference
TuHURA Biosciences (NASDAQ:HURA), a Phase 3 registration-stage immuno-oncology company, has announced its participation in the 37th Annual ROTH Conference in Dana Point, CA. The company's President and CEO, James A. Bianco, M.D., will engage in a fireside chat on March 18, 2025, at 8:30 AM PT.
TuHURA, which focuses on developing novel technologies to overcome resistance to cancer immunotherapy, will make the presentation available via live webcast on their company website's Investors section. Additionally, the management team will be available for one-on-one meetings with qualified registered conference attendees.
TuHURA Biosciences (NASDAQ:HURA), una compagnia di immuno-oncologia in fase di registrazione di Fase 3, ha annunciato la sua partecipazione alla 37ª Conferenza Annuale ROTH a Dana Point, CA. Il Presidente e CEO dell'azienda, James A. Bianco, M.D., parteciperà a una chiacchierata informale il 18 marzo 2025, alle 8:30 AM PT.
TuHURA, che si concentra sullo sviluppo di tecnologie innovative per superare la resistenza all'immunoterapia contro il cancro, renderà disponibile la presentazione tramite webcast dal vivo nella sezione Investitori del proprio sito web. Inoltre, il team di gestione sarà disponibile per incontri individuali con i partecipanti registrati qualificati alla conferenza.
TuHURA Biosciences (NASDAQ:HURA), una empresa de inmuno-oncología en etapa de registro de Fase 3, ha anunciado su participación en la 37ª Conferencia Anual ROTH en Dana Point, CA. El Presidente y CEO de la compañía, James A. Bianco, M.D., participará en una charla informal el 18 de marzo de 2025, a las 8:30 AM PT.
TuHURA, que se centra en desarrollar tecnologías novedosas para superar la resistencia a la inmunoterapia contra el cáncer, hará que la presentación esté disponible a través de una transmisión en vivo en la sección de Inversores de su sitio web. Además, el equipo de gestión estará disponible para reuniones individuales con los asistentes registrados calificados de la conferencia.
TuHURA Biosciences (NASDAQ:HURA), 3상 등록 단계의 면역 종양학 회사가 캘리포니아 다나 포인트에서 열리는 제37회 연례 ROTH 컨퍼런스에 참여한다고 발표했습니다. 회사의 회장 겸 CEO인 James A. Bianco, M.D.는 2025년 3월 18일 오전 8시 30분 PT에 파이어사이드 채팅에 참여할 예정입니다.
암 면역 요법에 대한 저항성을 극복하기 위한 혁신적인 기술 개발에 집중하는 TuHURA는 회사 웹사이트의 투자자 섹션을 통해 생중계로 발표를 제공할 것입니다. 또한, 경영진 팀은 등록된 자격을 갖춘 참석자들과의 일대일 회의도 진행할 예정입니다.
TuHURA Biosciences (NASDAQ:HURA), une entreprise d'immuno-oncologie en phase d'enregistrement de phase 3, a annoncé sa participation à la 37e Conférence Annuelle ROTH à Dana Point, CA. Le Président et CEO de l'entreprise, James A. Bianco, M.D., participera à une discussion informelle le 18 mars 2025 à 8h30 PT.
TuHURA, qui se concentre sur le développement de technologies novatrices pour surmonter la résistance à l'immunothérapie contre le cancer, mettra la présentation à disposition via un webinaire en direct dans la section Investisseurs de son site web. De plus, l'équipe de direction sera disponible pour des réunions individuelles avec les participants qualifiés enregistrés à la conférence.
TuHURA Biosciences (NASDAQ:HURA), ein Unternehmen der Immunonkologie in der Phase-3-Registrierungsstufe, hat seine Teilnahme an der 37. jährlichen ROTH-Konferenz in Dana Point, Kalifornien, bekannt gegeben. Der Präsident und CEO des Unternehmens, James A. Bianco, M.D., wird am 18. März 2025 um 8:30 Uhr PT an einem informellen Gespräch teilnehmen.
TuHURA, das sich auf die Entwicklung neuartiger Technologien zur Überwindung der Resistenz gegen die Krebsimmuntherapie konzentriert, wird die Präsentation über einen Live-Stream im Bereich Investoren auf der Unternehmenswebsite zur Verfügung stellen. Darüber hinaus wird das Management-Team für Einzelgespräche mit qualifizierten registrierten Konferenzteilnehmern zur Verfügung stehen.
- None.
- None.
Live webcast fireside chat on Tuesday, March 18th at 8:30 AM PT
TAMPA, FL / ACCESS Newswire / March 10, 2025 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA, will participate in a fireside chat on Tuesday, March 18, 2025 at 8:30 AM PT at the 37th Annual ROTH Conference being held in Dana Point, CA.
In addition to the presentation, management will be available to participate in one-on-one in-person meetings with qualified members of the investor community who are registered to attend the conference. For more information about the event, please visit the conference website.
A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company's website (tuhurabio.com).
About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer.
TuHURA's lead innate immune agonist drug candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate in second quarter 2025, a single randomized placebo-controlled Phase 3 registration=directed trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® and placebo in first=line treatment for advanced or metastatic Merkel Cell Carcinoma.
In addition to its innate immune agonist candidates, following the closing of the previously announced proposed merger with Kineta, TuHURA plans to advance its VISTA inhibiting antibody into a phase two trial in combination with a menin inhibitor in NPM1 mutated relapsed or refractory AML. Leveraging its discovery of the central role the Delta Opioid Receptor plays in modulating the immunosuppressive effects of myeloid derived suppressor cells (MDSCs) and tumor associated M2 polarized macrophages on the tumor microenvironment (TME), the Company is also developing non-tumor targeting ADCs and APCs to convert the TME to an immunogenic phenotype, potentially overcoming acquired resistance to checkpoint inhibitors and cellular therapies.
For more information, please visit tuhurabio.com and connect with TuHURA on Facebook, X, and LinkedIn.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
tuhura@jtcir.com
SOURCE: TuHURA Biosciences, Inc.
View the original press release on ACCESS Newswire
FAQ
When is TuHURA Biosciences (HURA) presenting at the ROTH Conference 2025?
How can investors watch TuHURA's (HURA) ROTH Conference presentation?
What type of presentation will HURA deliver at the ROTH Conference?
What is TuHURA Biosciences' (HURA) current development stage?
